These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38011702)

  • 1. Two-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Donors With Hepatitis C Viremia to Recipients Without Hepatitis C Viremia: A Small Uncontrolled Trial.
    Desai NM; Leung SG; Motter JD; Segev DL; Warren D; Durand CM
    Ann Intern Med; 2023 Dec; 176(12):1682-1684. PubMed ID: 38011702
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessing Tissue Transmission of Hepatitis C Virus From Viremic Donor to Seronegative Kidney Transplant Recipients: A Case Series.
    Franco A; Gosalvez C; Gimeno A; Trigueros M; Balibrea N; Perez Contreras FJ
    Transpl Int; 2023; 36():11110. PubMed ID: 37534060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transplantation of kidneys from HCV viremic donors to HCV viremic recipients followed by early direct acting antiviral therapy without ribavirin.
    Kapila N; Flocco G; Al Khalloufi K; Zervos XB
    J Viral Hepat; 2019 Mar; 26(3):407-409. PubMed ID: 30449062
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Impact of Donor Hepatitis C Virus on Kidney Transplant Outcomes for Hepatitis C-Positive Recipients in the Direct-Acting Antiviral Era: Time to Revise the Kidney Donor Risk Index?
    Goldfarb DA
    J Urol; 2020 Dec; 204(6):1369. PubMed ID: 32955983
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients.
    Friebus-Kardash J; Gäckler A; Kribben A; Witzke O; Wedemeyer H; Treckmann J; Herzer K; Eisenberger U
    Transpl Infect Dis; 2019 Oct; 21(5):e13146. PubMed ID: 31306562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver, simultaneous liver-kidney, and kidney transplantation from hepatitis C-positive donors in hepatitis C-negative recipients: A single-center study.
    Crismale JF; Khalid M; Bhansali A; De Boccardo G; Khaim R; Florman SS; Shapiro R; Schiano TD
    Clin Transplant; 2020 Jan; 34(1):e13761. PubMed ID: 31808193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of kidney transplantation from HCV-viremic donors into HCV-negative recipients.
    Daloul R; Pesavento TE; Goldberg DS; Reese PP
    Kidney Int; 2021 Dec; 100(6):1190-1198. PubMed ID: 34237327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-Year Allograft Survival for Recipients of Kidney Transplants From Hepatitis C Virus Infected vs Uninfected Deceased Donors in the Direct-Acting Antiviral Therapy Era.
    Schaubel DE; Tran AH; Abt PL; Potluri VS; Goldberg DS; Reese PP
    JAMA; 2022 Sep; 328(11):1102-1104. PubMed ID: 35994263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Four-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Hepatitis C-Viremic Donors to Hepatitis C-Negative Recipients: An Open-Label Nonrandomized Study.
    Durand CM; Barnaba B; Yu S; Brown DM; Chattergoon MA; Bair N; Naqvi FF; Sulkowski M; Segev DL; Desai NM
    Ann Intern Med; 2021 Jan; 174(1):137-138. PubMed ID: 32894697
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Ultra-Short Duration Direct Acting Antiviral Prophylaxis to Prevent Virus Transmission from Hepatitis C Viremic Donors to Hepatitis C Negative Kidney Transplant Recipients.
    Goldfarb DA
    J Urol; 2020 Oct; 204(4):868. PubMed ID: 32701370
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of Early Initiation of Direct-Acting Antiviral Therapy in Thoracic Organ Transplantation From Hepatitis C Virus Positive Donors.
    Smith DE; Chen S; Fargnoli A; Lewis T; Galloway AC; Kon ZN; Moazami N
    Semin Thorac Cardiovasc Surg; 2021; 33(2):407-415. PubMed ID: 32621962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kidney Transplantation From Hepatitis C Virus-Infected Donors to Uninfected Recipients: A Systematic Review for the KDIGO 2022 Hepatitis C Clinical Practice Guideline Update.
    Gordon CE; Adam GP; Jadoul M; Martin P; Balk EM
    Am J Kidney Dis; 2023 Oct; 82(4):410-418. PubMed ID: 37061019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients.
    Gupta G; Yakubu I; Bhati CS; Zhang Y; Kang L; Patterson JA; Andrews-Joseph A; Alam A; Ferreira-Gonzalez A; Kumar D; Moinuddin IK; Kamal L; King AL; Levy M; Sharma A; Cotterell A; Reichman TW; Khan A; Kimball P; Stiltner R; Baldecchi M; Brigle N; Gehr T; Sterling RK
    Am J Transplant; 2020 Mar; 20(3):739-751. PubMed ID: 31652392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients.
    Woolley AE; Singh SK; Goldberg HJ; Mallidi HR; Givertz MM; Mehra MR; Coppolino A; Kusztos AE; Johnson ME; Chen K; Haddad EA; Fanikos J; Harrington DP; Camp PC; Baden LR;
    N Engl J Med; 2019 Apr; 380(17):1606-1617. PubMed ID: 30946553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kidney Transplantation From Hepatitis-C Viraemic Donors:Considerations for Practice in the United Kingdom.
    Doherty DT; Athwal V; Moinuddin Z; Augustine T; Prince M; van Dellen D; Khambalia HA
    Transpl Int; 2022; 35():10277. PubMed ID: 35592447
    [No Abstract]   [Full Text] [Related]  

  • 16. Association between ezetimibe usage and hepatitis C RNA levels in uninfected kidney transplant recipients who received hepatitis C infected kidneys.
    Azhar A; Binari LA; Joglekar K; Tsujita M; Talwar M; Balaraman V; Bhalla A; Eason JD; Hall IE; Rofaiel G; Forbes RC; Shaffer D; Concepcion BP; Molnar MZ
    Clin Transplant; 2021 Dec; 35(12):e14485. PubMed ID: 34523744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection.
    Sise ME; Goldberg DS; Kort JJ; Schaubel DE; Alloway RR; Durand CM; Fontana RJ; Brown RS; Friedewald JJ; Prenner S; Landis JR; Fernando M; Phillips CC; Woodle ES; Rike-Shields A; Sherman KE; Elias N; Williams WW; Gustafson JL; Desai NM; Barnaba B; Norman SP; Doshi M; Sultan ST; Aull MJ; Levitsky J; Belshe DS; Chung RT; Reese PP
    J Am Soc Nephrol; 2020 Nov; 31(11):2678-2687. PubMed ID: 32843477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kidney transplant from hepatitis C viremic donors into aviremic recipients and risk for post-transplant BK and cytomegalovirus infection.
    Daloul R; Schnelle K; Von Stein L; Logan A; Singh P; Yenebere P; Pesavento T; Washburn K
    Transpl Infect Dis; 2022 Aug; 24(4):e13887. PubMed ID: 35752929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Donor Hepatitis C Virus on Kidney Transplant Outcomes for Hepatitis C-positive Recipients in the Direct-acting Antiviral Era: Time to Revise the Kidney Donor Risk Index?
    Cannon RM; Locke JE; Orandi BJ; Anderson DJ; Davis EG; Mackelaite L; Dave H; Eng M; Jones CM
    Transplantation; 2020 Jun; 104(6):1215-1228. PubMed ID: 31517783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
    Durand CM; Bowring MG; Brown DM; Chattergoon MA; Massaccesi G; Bair N; Wesson R; Reyad A; Naqvi FF; Ostrander D; Sugarman J; Segev DL; Sulkowski M; Desai NM
    Ann Intern Med; 2018 Apr; 168(8):533-540. PubMed ID: 29507971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.